Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.

Abstract: The invention relates to a fixation system between a medical device and at least one portion of a bone, characterised in that it comprises an elongate portion intended to be inserted into the bone, in particular into the medullary cavity and/or into the proximal or distal ends, the elongate portion having a wall consisting of meshes through which at least one fixing member can pass, according to a position and orientation that are not predefined, and which apply, by elastic, plastic or elastic-plastic deformation, a transverse and/or axial pressure force onto the fixing member, the fixing member being intended to also pass through the portion of the bone in order to ensure rigid fixation between the bone and the medical device.

Abstract: The invention relates to a shoulder prosthesis comprising a diaphyseal part extending along a diaphyseal axis and on which an epiphyseal part is mounted, the epiphyseal part having an upper face which is inclined along a front plane with respect to the diaphyseal axis, and a lower central face bearing against a complementary upper face of the diaphyseal part. According to the invention, the epiphyseal part is reversible by rotation through 180° about an axis normal to the lower central face bearing against the epiphyseal part to modify the inclination of the upper face of the epiphyseal part.

Abstract: The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells.

Abstract: The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.

Abstract: The present invention relates to a method for reducing CD95-mediated cell motility. To identify chemicals disrupting CD95/PLC?1 interaction, the inventors screened a chemical library of EMA/FDA-approved molecules against a protein-fragment complementation assay (PCA) monitoring the binding of CD95 to PLC?1. From this screen, five chemical molecules showed the ability to disrupt CD95/PLC?1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to a method for reducing CD95-mediated cell motility, comprising administering the subject with at least one compound selected from the group consisting of HIV-protease inhibitors (e.g. ritonavir), diflunisal, anethole, rosiglitazone and daunorubicin.

Abstract: The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility.

Abstract: The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.

Abstract: The present invention relates to polypeptides and uses thereof for reducing CD95-meditated cell motility. In particular, the present invention relates to a polypeptide having an amino acid sequence having at least 70% of identity with the amino acid sequence ranging from the amino-acid residue at position 175 to the amino-acid residue at position 191 in SEQ ID NO:1.

Abstract: Surgical implant for treating fractures of long bones, notably of the femur, having an intramedullary section (52) of elongated shape, adapted for being inserted into the medullary cavity (37), an extramedullary section (56) substantially parallel to the intramedullary section (52), a deformable curved loop (57) connecting the intramedullary section (52) to the extramedullary section (56), an inclined screw (61) traversing said intramedullary section (52) and said extramedullary section (56). By deforming the loop (57), a continuous adjustment of the angle (?) of the cephalic screw (61) and thus an optimal adaptation of the implant to the individual anatomy can be achieved. Thanks to its geometry, this implant induces a protection of the greater trochanter and limits the mechanical loads between the cephalic screw (61) and the rest of the implant.

Abstract: The present invention concerns a composition for potentiating formation of DISC (Death Inducing Signaling Complex) macro-complex and for inducing apoptotic signal mediated by death receptors in tumour cells comprising a therapeutically effective amount of an active agent selected among a hypocalcemia-inducing agent, a calcium channel inhibitor and a calcium chelator in association with a therapeutically effective amount of an anticancer agent inducing an apoptotic signal via death receptors Fas, TNF-R1, DR4 and/or DR5.

Abstract: The line-sweep power circuit is of the known type, in which the base current of the switching transistor (TP) is automatically maintained by a positive feedback provided by a winding (L2) of the EHT transformer. This circuit is synchronized by a signal transmitted by an opto-coupler (DE-TC). The duty factor of the control signal transmitted by the opto-coupler is modified in a progressive manner during the transitions of a start signal (RC) so as to interrupt the conductance of the power transistor at an ever earlier instant. This may be obtained, for example, by means an integrator (4, 8) to which the load resistor (R2) of a transistor (T0) with an open collector is connected, which is driven by a line synchronizing signal.

Abstract: This circuit includes an arrangement which modulates the horizontal velocity of the spot as a function of the video contents with the aid of a supplementary horizontal deflection coil. This arrangement essentially includes a video signal differentiator followed by an amplifier which supplies a current to the supplementary deflection coil. The current generated by the amplifier has a threshold (S) for the input signal, and a quasi-plateau for input signals beyond 25%. The difference between this current and the current which would be generated by a linear amplifier (broken-line curve) is concerned in this case. This difference, for example for an input voltage of 50%, is referred to as reserve (R). A trap filter is inserted upstream of the amplifier in the arrangement, which filter is centered on the chrominance subcarrier frequency and has a depth which is equal to about the value of the reserve.

Abstract: A switched-mode power supply having at least two output terminals for supplying at least two different voltages and capable of operating in an alternate state in which some of the voltages are reduced. The power supply includes at least two controllable voltage sources coupled, respectively, to the output terminals and at least one voltage regulating circuit coupled to control inputs of the voltage sources for reducing the output voltages of both voltage sources proportionately when the voltage on the output of a first one of the voltage sources exceeds a preset reference level. The power supply further includes a circuit for selectively coupling a second one of the voltages sources to the regulating circuit.

Abstract: The bogie of a railroad vehicle, in particular for city transportation, is provided with axles which can be oriented substantially along the radius of the curves of a railroad track. The primary suspension of the bogie comprises springs and guiding link-arms of variable length constituted by hydraulic jacks for modifying the angle of the axle with respect to the bogie frame according to the radius of the curve being negotiated.